Belgium-based UCB Inc,a global biopharmaceutical company focusing on central nervous system and immunology treatment and research,has filed separate patent infringement cases against as many as 15 drug makers in a Delaware court to prevent generic drug makers such as Ranbaxy,Aurobindo,Sun Pharma,Glenmark,Sandoz,Glenmark,Watson from entering the market with versions of its epilepsy treatment drug Vimpat.
Vimpat (Lacosamide) is indicated as an add-on therapy for the treatment of partial-onset seizures in adults with epilepsy. According to a petition filed by UCB Inc,UCB Pharma GmBH,Research Corporation Technologies Inc and Harris FRC Corporation,the patent of its lacosamide tablets would expire on March 17,2022.
According to IMS Health data,Vimpat had US sales of approximately $353 million for the 12 months ended March 31. According to the petitioners,the patent,which belonged to Arizona-based Research Corporation Technologies Inc,was licensed to Harris FRC Corp of New Jersey. Harris,in turn sub-licensed the patent to German drugmaker Schwartz Pharma AG. Schwarg was later acquired by UCB SA along with rights on Lacosamide. The licence agreement between Harris and was restated and amended for all countries by and among Harris,UCB Pharma GmBH and UCB SA.
The petitioners requested the court to issue a permanent injunction and enjoin the respondents from engaging in the commercial manufacture,offer to sell or import until the expiration of the patent,or any later date of exclusivity to which the petitioners are entitled.